Developing therapeutics for schizophrenia and other psychotic disorders.

ABSTRACT: Although the second-generation or atypical antipsychotic drugs have been breakthrough medicines for the treatment of schizophrenia and other psychotic conditions, cognitive dysfunction and to some extent negative symptoms of the disease continue to be the main cause of poor vocational status of the patients. Thus, the majority of investigational drug development efforts today target these unmet medical needs. This review postulates that the field of schizophrenia research has advanced sufficiently to develop biochemical hypotheses of the etiopathology of the disease and target the same for revolutionary disease modifying therapy. This postulate is based on recent studies that have begun to provide a testable etiopathology model that integrates interactions between genetic vulnerability fac

SUBMITTER: Marek G 

PROVIDER: S-EPMC1201317 | biostudies-literature | 2005 Oct

REPOSITORIES: biostudies-literature